Asset Details
Do you wish to reserve the book?
Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
Do you wish to request the book?
Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Hypertension complicating 131I-meta-iodobenzylguanidine therapy for neuroblastoma
2012
Overview
Purpose
Radiolabelled
meta
-iodobenzylguanidine (mIBG), used as targeted therapy for neuroblastoma, is known to have effects on blood pressure (BP). In this study we audited BP changes in patients receiving
131
I-mIBG therapy for neuroblastoma to identify BP-related adverse events (AE) and possible predictive factors.
Methods
Between 2003 and 2010, 50 patients with neuroblastoma received 110
131
I-mIBG administrations. BP measurements before and after administration were compared with age- and sex-matched centile values. AE were analysed, and possible predisposing factors identified.
Results
This population had a baseline BP distribution higher than that of their age- and sex-matched peers, with 16% of preadministration systolic BP values above the 95th centile. Changes in BP after administration showed an approximately normal distribution with similar numbers of reduced and increased values. Four AE, all related to hypertension, occurred with one patient having generalized seizures. One AE was immediate, others occurred between 20 and 25 h after administration. No significant association between AE and patient age or sex was demonstrated. However, a significant association between AE and high preadministration BP was shown, both above the 90th centile (
p
= 0.0022) and above the 95th centile (
p
= 0.0135).
Conclusion
Clinically relevant hypertension following
131
I-mIBG therapy affected less than 5% of administrations, but was more common in those patients with preexisting hypertension. As hypertensive episodes may occur many hours after treatment, close monitoring of BP needs to be continued for at least 48 h after administration of
131
I-mIBG.
Publisher
Springer-Verlag
Subject
3-Iodobenzylguanidine - adverse effects
/ 3-Iodobenzylguanidine - therapeutic use
/ Blood Pressure - radiation effects
/ Child
/ Female
/ Humans
/ Hypertension - complications
/ Imaging
/ Male
/ Medicine
/ Neuroblastoma - complications
/ Neuroblastoma - physiopathology
/ Neuroblastoma - radiotherapy
/ Oncology
